Glenmark Pharmaceuticals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for GLENMARK, BSE:532296 Glenmark Pharmaceuticals Ltd.

Glenmark Pharmaceuticals Ltd.

14 Aug 2019

2071.80

1.44%

Glenmark Pharma-1QFY20 Result Update

Hold: Glenmark Pharmaceuticals Ltd.

Target

Reliance Securities

No Meaningful Upside in Sight; Maintain HOLD Glenmark Pharmaceuticals (GNP) has delivered disappointing performance on all metrics in 1QFY20 due to weak growth across all geographies barring India. Its revenue/EBITDA missed our estimate by 6%/10%, respectively while EBITDA margin came in line with our estimate. Revenue declined by 9% QoQ to Rs23.2bn. US business fell by 4% QoQ to US$105mn, while India Business grew by 13% (both on YoY and QoQ basis) to Rs7.5bn. It recorded 12% growth vs. IPM growth of ~10% (IQVIA MAT Jun'19), while consumer business grew by 27% YoY to Rs556mn. GNP's Baddi formulation facility classified as (inspection 15-20th Apr'19) Official Action Indicated...

Glenmark Pharmaceuticals Ltd.'s price crossed above 50Day SMA today

Glenmark Pharmaceuticals Ltd.

31 May 2019

2071.80

1.44%

Glenmark (4QFY19): Value-unlocking at play. Maintain BUY

Buy: Glenmark Pharmaceuticals Ltd.

Target

HDFC Securities

Despite weaker US performance and lower profitability, we remain positive on the stock due to expected value unlocking from the listing of the novel subsidiary and potential debt reduction on account of divestment of non-core assets. We believe the de-merger will lead to better profitability for the ex-novel business and an improved balance sheet (debt reduction and lower intangibles). We value the novel and specialty businesses at Rs 135/sh (value of the base business stands at Rs 595/sh, 16x FY21E EPS). However, we believe this listing could take anywhere between 12-15 months. We maintain BUY on GNP despite reporting marginal miss in profitability. Lower US sales due to the gMupirocin stock-out situation was the key reason. TP has been reduced to Rs 730/sh on account of weaker guidance for the US generics business.

Glenmark Pharmaceuticals Ltd. has gained 44.92% in the last 6 Months

Glenmark Pharmaceuticals Ltd.

31 May 2019

2071.80

1.44%

Heavy promo spend cause sprain in earnings; Restructuring in progress Sales largely in-line led by R

Neutral: Glenmark Pharmaceuticals Ltd.

Target

Motilal Oswal

Heavy promo spend cause sprain in earnings; Restructuring in progress Sales largely in-line led by ROW/API: Sales increased 12% YoY to INR25b (our estimate: INR25.5b), led by growth of 29% YoY (to INR4b) in ROW sales and 21% YoY (to INR2.5b) in API sales. India sales grew at a moderate rate of 9.7% YoY to INR7b, while US sales were up 10% YoY at INR7.7b, largely supported by FX tailwinds. Gross margin (GM) improved 80bp YoY to 65.9% due to a superior product mix. EBITDA margin expanded 80bp YoY to 13.9% (our estimate: 15.9%), led by higher GM and lower opex (adjusting for one-time expense of INR250m...

Glenmark Pharmaceuticals Ltd. has gained 25.32% in the last 3 Months

Glenmark Pharmaceuticals Ltd.

30 May 2019

2071.80

1.44%

Glenmark Pharma -4QFY19 Result Update

Hold: Glenmark Pharmaceuticals Ltd.

Target

Reliance Securities

Glenmark Pharmaceuticals Ltd. has gained 25.32% in the last 3 Months

Glenmark Pharmaceuticals Ltd.

30 May 2019

2071.80

1.44%

Glenmark Pharmaceuticals

Hold: Glenmark Pharmaceuticals Ltd.

Target

ICICI Securities Limited

US generics comprise 32% of total revenues. So far, the company has received approval for 152 ANDAs while another 53 are pending approval, of which 28 are Para IV applications. Key therapies in the US, going forward, will be oncology dermatology and respiratory. The company expects to launch 12-15 products. We expect the US to grow at 4.5% CAGR in FY1921E to | 3427 crore mainly due high base and lack of meaningful launches. Targeting specific therapies in IPM Glenmark is ranked fourteenth in domestic formulations with a market share of 2.2%. It is a market leader in dermatology and improving its presence in...

Glenmark Pharmaceuti.. has an average target of 2144.00 from 5 brokers.

Glenmark Pharmaceuticals Ltd.

30 May 2019

2071.80

1.44%

Glenmark

Hold: Glenmark Pharmaceuticals Ltd.

Sharekhan

(Glenmark) reported sales growth of 12.4% y-o-y to Rs. 2,563.5 crore (in line with estimates). Operating profit grew by 11.3% y-o-y to Rs. 363.8 crore (16% below estimates). OPM declined by 14 BPS y-o-y to 14.2% (266 BPS lower than our estimate of 16.9%). The decline in operating profit was mainly due to high other expenses. Adjusted profit for the quarter grew by 22%...

Glenmark Pharmaceuticals Ltd. has gained 25.32% in the last 3 Months

Glenmark Pharmaceuticals Ltd.

18 Feb 2019, 12:00AM

2071.80

1.44%

Glenmark Pharmaceuticals: Q3FY19 Result Review

Accumulate: Glenmark Pharmaceuticals Ltd.

IDBI Capital

Glenmark reported Q3 results broadly in line but forex loss of Rs1.15bn restricted the growth in earnings at 11% YoY. Innovative business (R&D; assets) to be spun off by creating a wholly owned subsidiaries for a better focus and value unlocking in course of time. The API business has been transferred to wholly owned subsidiary Glenmark Life Science (GLS) w.e.f. 1st Jan'19;...

Glenmark Pharmaceuticals Ltd. has gained 44.92% in the last 6 Months

Glenmark Pharmaceuticals Ltd.

16 Feb 2019, 11:50AM

2071.80

1.44%

Glenmark (3QFY19): In-line quarter. Maintain BUY

Buy: Glenmark Pharmaceuticals Ltd.

Target

HDFC Securities

Maintain buy with a TP of Rs 800 (16x Dec-21E EPS + Rs 135/sh for pipeline). Glenmark reported broadly in-line numbers as revenues grew 16% YoY to Rs 25.6bn, and EBITDA came in at Rs 4.3bn with 17% margin. However, PAT at Rs 1.2bn was much lower than expectation owing to a Rs 1.3bn forex loss included in other income.

Geojit BNP Paribas increased Accumulate price target of Glenmark Pharmaceuticals Ltd. to 2306.0 on 09 Sep, 2025.

Glenmark Pharmaceuticals Ltd.

15 Feb 2019

2071.80

1.44%

Glenmark Pharma -3QFY19 Result Update

Glenmark Pharmaceuticals Ltd.

Reliance Securities

Glenmark Pharmaceuticals Ltd. is trading above all available SMAs

Glenmark Pharmaceuticals Ltd.

15 Feb 2019

2071.80

1.44%

Glenmark Pharmaceuticals

Hold: Glenmark Pharmaceuticals Ltd.

Target

ICICI Securities Limited

Q3FY19 results were in line with I-direct estimates on the operational front. However, net profit was lower mainly due to forex loss Revenues grew 15.9% YoY to | 2555 crore (I-direct estimate: | 2521.0 crore) mainly due to 43.2% growth in Europe to | 321.7 crore (I-direct estimate: | 269.7 crore) and 16.3% growth in the US to | 855.7 crore (I-direct estimate: | 847.9 crore) EBITDA margins improved 237 bps YoY to 17% (in-line with I-direct estimates of 17.4%) mainly due to a 173 bps improvement in gross...

Glenmark Pharmaceuticals Ltd. is trading above all available SMAs

Is Glenmark Pharmaceuticals Ltd. worth buying?

571 Votes:

Buy 79.33%

Sell 13.66%

Hold 7.01%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf